[A25-100 ] Odronextamab (DLBCL) – Benefit assessment according to § 35a SGB V
Last updated 03.11.2025
Project no.:
A25-100
Commission:
Commission awarded on 31.07.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with relapsed or refractory diffuse large B-cell lymphoma, after at least 2 prior systemic therapies
Result of dossier assessment:
- Patients who are eligible for CAR T-cell therapy or stem cell transplantation: added benefit not proven
- Patients who are ineligible for CAR T-cell therapy or stem cell transplantation: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-100
| Project no. | Title | Status |
|---|---|---|
| A25-101 | Odronextamab (follicular lymphoma) – Benefit assessment according to § 35a SGB V | Commission completed |